REGENXBIO Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer
REGENXBIO Inc. (RGNX) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer of $0 as of 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger · last filed 2026-03-05
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
- 2025-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $2.74M.
- 2025-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $8.97M.
- 2024-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $24.14M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer |
|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.74M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $8.97M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $24.14M 10-K · filed 2026-03-05 |
| 2024-09-30 | $54.71M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $91.64M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $143.58M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $202.59M 10-K · filed 2025-03-13 |
| 2023-09-30 | $239.37M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $277.06M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $356.37M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $263.82M 10-K · filed 2024-02-27 |
| 2022-09-30 | $140.03M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $88.61M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $72.72M 10-Q · filed 2022-05-04 |
| 2019-03-31 | $2.00M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $12.42M 10-K · filed 2019-02-27 |
| 2018-09-30 | $10.59M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $21.07M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |